PVP-037.2

Name: PVP-037.2
Brand: MedChemExpress
SKU: HY-159102
Rating: 4.5 (0 reviews)

Cat. No.: HY-159102 Purity: 98.40%: Data Sheet
COA

SDS
Handling Instructions
FAQs
Technical Support

PVP-037.2 is a TLR7/8 agonist. PVP-037.2 can serve as an adjuvant to enhance vaccine-induced T_H1 type immune responses, increasing the production of antigen-specific antibodies IgG1 and IgG2c.

For research use only. We do not sell to patients.

PVP-037.2 Chemical Structure

CAS No. : 3049666-32-9

Size	Stock	Quantity
Solid + Solvent (Highly Recommended)
10 mM * 1 mL in DMSO ready for reconstitution	In-stock	Estimated Time of Arrival: December 31
Solution
10 mM * 1 mL in DMSO	In-stock	Estimated Time of Arrival: December 31
Solid
5 mg	In-stock	Estimated Time of Arrival: December 31
10 mg	In-stock	Estimated Time of Arrival: December 31
25 mg	In-stock	Estimated Time of Arrival: December 31
50 mg	In-stock	Estimated Time of Arrival: December 31
100 mg	In-stock	Estimated Time of Arrival: December 31
200 mg	Get quote
500 mg	Get quote

or Bulk Inquiry

* Please select Quantity before adding items.

This product is a controlled substance and not for sale in your territory.

Customer Review

Based on 1 Customer Validation

Featured Recommendations

•Related Screening Libraries:

•Related Small Molecules:

•Related Proteins:

View All Toll-like Receptor (TLR) Isoform Specific Products:

View All Isoforms

TLR3 TLR8 TLR9 TLR2 TLR4 TLR7 TLR1 TLR6

Biological Activity
Purity & Documentation
References
Customer Review

Description

PVP-037.2 is a TLR7/8 agonist. PVP-037.2 can serve as an adjuvant to enhance vaccine-induced T_H1 type immune responses, increasing the production of antigen-specific antibodies IgG1 and IgG2c^[1].

IC₅₀ & Target

TLR7

TLR8

In Vitro

PVP-037.2 (0.1-100 μM, 24 h) induces concentration-dependent production of TNF and IL-1β in human elder peripheral blood mononuclear cells (PBMCs)^[1].
PVP-037.2 ((100 μM, 20-24 h) demonstrates a TLR7/8-dependent immunomodulatory profile^[1].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

In Vivo

PVP-037.2 (3 mg/kg, i.v., measured 0-8 hours post-administration) shows high plasma clearance and almost no hemolytic activity in adult C57BL/6J mice (20 to 30 g in weight)^[1].
PVP-037.2 (100 nmol per mouse, i.v., single immunization) exhibits potent adjuvant effects in C57BL/6J mice immunized with the trivalent recombinant rHA influenza vaccine Flublok and SARS-CoV-2 spike protein^[1].
Compared with the use of PVP-037.2 alone, the PVP-037.2 O/W emulsion formulation (10 nmol per mouse, i.v., IgG titer measured on day 42) enhances the innate immune activation capability in wild-type C57BL/6J mice^[1].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

Animal Model:	WT C57BL/6J mice
Dosage:	10 nmol per mouse
Administration:	Intravenous injection (i.v.), single injection
Result:	Significantly enhanced total IgG and IgG2c class-switched antibody responses (IgG titers measured on day 42).

Animal Model:	C57BL/6J mice (6 to 8 weeks old, stimulated with the trivalent recombinant rHA influenza vaccine Flublok and the SARS-CoV-2 spike protein)
Dosage:	100 nmol per mouse
Administration:	Intravenous injection (i.v.), single injection
Result:	Resulted that the production of antigen-specific IgG1 and IgG2c was significantly enhanced in C57BL/6J mice stimulated with the trivalent recombinant rHA influenza vaccine Flublok (IgG titers measured on day 28) and the SARS-CoV-2 spike protein (IgG titers measured on day 42).

Molecular Weight

439.43

Formula

C₂₃H₂₀F₃N₅O

CAS No.

3049666-32-9

Appearance

Solid

Color

White to yellow

SMILES

CC1=CN2C=C(N=C2N=C1)C3=CC(NC(C4=C(C=C(C=C4)CN)C(F)(F)F)=O)=C(C=C3)C

Shipping

Room temperature in continental US; may vary elsewhere.

Storage

Powder	-20°C	3 years
In solvent	-80°C	6 months
	-20°C	1 month

Solvent & Solubility

In Vitro:

DMSO : 100 mg/mL (227.57 mM; ultrasonic and warming and heat to 60°C; Hygroscopic DMSO has a significant impact on the solubility of product, please use newly opened DMSO)

Preparing
Stock Solutions

Concentration Solvent Mass	1 mg	5 mg	10 mg

1 mM	2.2757 mL	11.3784 mL	22.7568 mL
5 mM	0.4551 mL	2.2757 mL	4.5514 mL
10 mM	0.2276 mL	1.1378 mL	2.2757 mL

View the Complete Stock Solution Preparation Table

* Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
Storage method and period of stock solution: -80°C, 6 months; -20°C, 1 month. When stored at -80°C, please use it within 6 months. When stored at -20°C, please use it within 1 month.

Molarity Calculator
Dilution Calculator

Mass (g) = Concentration (mol/L) × Volume (L) × Molecular Weight (g/mol)

Concentration _(start) × Volume _(start) = Concentration _(final) × Volume _(final)

This equation is commonly abbreviated as: C₁V₁ = C₂V₂

Concentration _(start)

Volume _(start)

Concentration _(final)

Volume _(final)

In Vivo:

Select the appropriate dissolution method based on your experimental animal and administration route.

For the following dissolution methods, please ensure to first prepare a clear stock solution using an In Vitro approach and then sequentially add co-solvents:
To ensure reliable experimental results, the clarified stock solution can be appropriately stored based on storage conditions. As for the working solution for in vivo experiments, it is recommended to prepare freshly and use it on the same day.
The percentages shown for the solvents indicate their volumetric ratio in the final prepared solution. If precipitation or phase separation occurs during preparation, heat and/or sonication can be used to aid dissolution.

Protocol 1

Add each solvent one by one: 10% DMSO 40% PEG300 5% Tween-80 45% Saline
Solubility: ≥ 2.5 mg/mL (5.69 mM); Clear solution

This protocol yields a clear solution of ≥ 2.5 mg/mL (saturation unknown).
Taking 1 mL working solution as an example, add 100 μL DMSO stock solution (25.0 mg/mL) to 400 μL PEG300, and mix evenly; then add 50 μL Tween-80 and mix evenly; then add 450 μL Saline to adjust the volume to 1 mL.
Preparation of Saline: Dissolve 0.9 g sodium chloride in ddH₂O and dilute to 100 mL to obtain a clear Saline solution.
Protocol 2

Add each solvent one by one: 10% DMSO 90% (20% SBE-β-CD in Saline)
Solubility: ≥ 2.5 mg/mL (5.69 mM); Clear solution

This protocol yields a clear solution of ≥ 2.5 mg/mL (saturation unknown).
Taking 1 mL working solution as an example, add 100 μL DMSO stock solution (25.0 mg/mL) to 900 μL 20% SBE-β-CD in Saline, and mix evenly.
Preparation of 20% SBE-β-CD in Saline (4°C, storage for one week): 2 g SBE-β-CD powder is dissolved in 10 mL Saline, completely dissolve until clear.
Protocol 3

Add each solvent one by one: 10% DMSO 90% Corn Oil
Solubility: ≥ 2.5 mg/mL (5.69 mM); Clear solution

This protocol yields a clear solution of ≥ 2.5 mg/mL (saturation unknown). If the continuous dosing period exceeds half a month, please choose this protocol carefully.
Taking 1 mL working solution as an example, add 100 μL DMSO stock solution (25.0 mg/mL) to 900 μL Corn oil, and mix evenly.

In Vivo Dissolution Calculator

Please enter the basic information of animal experiments:

Dosage

mg/kg

Animal weight
(per animal)

Dosing volume
(per animal)

μL

Number of animals

Recommended: Prepare an additional quantity of animals to account for potential losses during experiments.

Please enter your animal formula composition:

DMSO +

Tween-80 +

Saline

Recommended: Keep the proportion of DMSO in working solution below 2% if your animal is weak.

The co-solvents required include: DMSO, . All of co-solvents are available by MedChemExpress (MCE). , Tween 80. All of co-solvents are available by MedChemExpress (MCE).

Calculation results:

Working solution concentration: mg/mL

Method for preparing stock solution: mg drug dissolved in μL DMSO (Stock solution concentration: mg/mL).

The concentration of the stock solution you require exceeds the measured solubility. The following solution is for reference only. If necessary, please contact MedChemExpress (MCE).

Method for preparing in vivo working solution for animal experiments: Take μL DMSO stock solution, add μL . μL , mix evenly, next add μL Tween 80, mix evenly, then add μL Saline.

If the continuous dosing period exceeds half a month, please choose this protocol carefully.

Please ensure that the stock solution in the first step is dissolved to a clear state, and add co-solvents in sequence. You can use ultrasonic heating (ultrasonic cleaner, recommended frequency 20-40 kHz), vortexing, etc. to assist dissolution.

Purity & Documentation

Purity: 99.18%

Select Batch:

Data Sheet (274 KB) SDS (251 KB)

COA (249 KB) HNMR (332 KB) CNMR (264 KB) RP-HPLC (262 KB) LCMS (107 KB)

Handling Instructions (2659 KB)

References

[1]. Soni D, et al. From hit to vial: Precision discovery and development of an imidazopyrimidine TLR7/8 agonist adjuvant formulation[J]. Science Advances, 2024, 10(27): eadg3747. [Content Brief]

Complete Stock Solution Preparation Table

Optional Solvent	Concentration Solvent Mass	1 mg	5 mg	10 mg	25 mg

DMSO	1 mM	2.2757 mL	11.3784 mL	22.7568 mL	56.8919 mL
	5 mM	0.4551 mL	2.2757 mL	4.5514 mL	11.3784 mL
	10 mM	0.2276 mL	1.1378 mL	2.2757 mL	5.6892 mL
	15 mM	0.1517 mL	0.7586 mL	1.5171 mL	3.7928 mL
	20 mM	0.1138 mL	0.5689 mL	1.1378 mL	2.8446 mL
	25 mM	0.0910 mL	0.4551 mL	0.9103 mL	2.2757 mL
	30 mM	0.0759 mL	0.3793 mL	0.7586 mL	1.8964 mL
	40 mM	0.0569 mL	0.2845 mL	0.5689 mL	1.4223 mL
	50 mM	0.0455 mL	0.2276 mL	0.4551 mL	1.1378 mL
	60 mM	0.0379 mL	0.1896 mL	0.3793 mL	0.9482 mL
	80 mM	0.0284 mL	0.1422 mL	0.2845 mL	0.7111 mL
	100 mM	0.0228 mL	0.1138 mL	0.2276 mL	0.5689 mL

PVP-037.2 Related Classifications

Inflammation/Immunology

Help & FAQs

Do most proteins show cross-species activity?
Species cross-reactivity must be investigated individually for each product. Many human cytokines will produce a nice response in mouse cell lines, and many mouse proteins will show activity on human cells. Other proteins may have a lower specific activity when used in the opposite species.

Keywords:

PVP-037.23049666-32-9Toll-like Receptor (TLR)Peripheral blood mononuclear cells (PBMCs)C57BL/6J mice model (stimulated with the trivalent recombinant rHA influenza vaccine Flublok and the SARS-CoV-2 spike protein)AdjuvanticityInflammation/ImmunologyInhibitorinhibitorinhibit

Your Recently Viewed Products:

Product Name

Requested Quantity *

Applicant Name *

Salutation

Email Address *

Phone Number *

Department

Organization Name *

City

State

Country or Region *

Remarks

Product Name

Lot #

Applicant Name *

Email Address *

Phone Number

Department *

Organization Name *

Country or Region *

Remarks

Name
Email *

	Sorry, but the email address you supplied was invalid.

PVP-037.2

Customer Review

PVP-037.2 Related Antibodies

Featured Recommendations

•Related Screening Libraries:

•Related Small Molecules:

•Related Proteins:

View All Toll-like Receptor (TLR) Isoform Specific Products:

Biological Activity

Purity & Documentation

References

Customer Review

PVP-037.2 Related Antibodies

Molarity Calculator

Dilution Calculator

Complete Stock Solution Preparation Table

PVP-037.2 Related Classifications

Keywords:

Your Recently Viewed Products:

Customer Review

Request for HNMR Report

SAFETY DATA SHEET (SDS)

Request for HNMR Report